For more information on the conference, please click on the link http://www.frontierbsi.com/wp-content/uploads/2012/05/may151.pdf.

Bensalem, PA- February 5, 2011-  Xybion Corporation, a leading provider of preclinical R&D solutions, announced today that Chengdu Frontier BioSciences Co., a global contract research organization (CRO) has licensed Xybion’s Pristima suite to support end-to-end preclinical data management processes.  Chengdu Frontier BioSciences has also engaged Xybion’s Professional Services team to deliver full implementation including installation, instrument interfacing, training, and validation.  Chengdu Frontier BioSciences will be leveraging Pristima’s powerful capabilities including Colony Management, General Toxicology, Clinical Pathology and Pathology as part of its strategy to improve the entire safety assess process and to expand the wide variety of services Frontier BioSciences provides its client community.

Frontier’s CEO, Dr. Dong Xie, commented, “We are committed to continuously improving our accuracy and efficiency.  As such, the implementation of Pristima system will help elevate our level of performance, and ensure efficient delivery of data to our sponsors.  This decision is a key element to our goal of becoming a preeminent service-provider in the area of preclinical drug development.”  Further commenting, Frontier’s COO, Dr. Li Tian, remarked, “We selected Xybion after assessing the market, extensive consultation with our clients and industry experts, and in-depth familiarization of the software tools.  The system is very functional and user-friendly, requiring minimal training, and is supported by a world-class team.”

Dr. Pradip Banerjee, Xybion’s CEO, stated, “We are thrilled to add Chengdu Frontier BioSciences to Xybion’s client community and to expand our global footprint.   The Chinese drug development market is extremely active and full of promise so it is important that Xybion develops clients and partners in this market.”  Dr. Banerjee continued, “As a system that operates equally in Mandarin or English and is enterprise-grade application suite, we believe Pristima is the premier solution available to the China research and development market.”

Chengdu Frontier BioSciences, with its diverse services and high quality standards, selected Xybion’s Pristima solution to best meet its objectives in delivering high quality studies and final reports.  The selection of Pristima was the result of a comprehensive market assessment and consultation with Chengdu Frontier BioSciences’clients and industry experts.  Chengdu Frontier BioSciences selected Xybion based on several key factors including Xybion’s global market presence, strong preclinical data management credentials, and comprehensive professional service offerings.   With its global presence, Xybion will provide Chengdu  BioSciences with both remote and on-site implementation services to assure a successful deployment and a quick return on investment.

About Chengdu Frontier BioSciences Co.

Chengdu Frontier BioSciences, Inc., with toxicology facilities in Chengdu, China, and corporate office in Maryland, U.S.A., provides a full spectrum of drug discovery and development resources to biotechnology and pharmaceutical industries in the scientific disciplines of GLP-compliant toxicology, developmental and reproductive toxicology, pharmacology, genetic toxicology, pathology, analytical chemistry and international regulatory guidance.

About Xybion Corporation

Xybion Corporation is a global leader in the development and delivery of enterprise solutions that power innovation and efficiency.  We offer a comprehensive portfolio of solutions including Pre-clinical R&D data management (Pristima^®), enterprise governance/risk/compliance (eGRC), Enterprise Asset Management, Enterprise Content/Records Management, automated testing and Quality Solutions for clients across multiple industry sectors.  Xybion’s practical industry solutions are broadly adopted by leading companies across the globe.  Xybion compliments its product and services portfolio with a broad range of professional services designed to help organizations achieve higher levels of performance, efficiency, compliance and sustained corporate governance.

Mr. Stashick has over 20 years experience in the research field, and over 14 years experience in Quality Assurance management with experience in GLP, GMP, ISO 9001 and ISO 13485.  Prior to joining the staff of Frontier he was employed by ExonHit Therapeutics, where he served as Manager of Quality Assurance.  While employed by ExonHit, Joe was responsible for the development of a GLP compliant program, from the ground up.

Mr. Stashick’s strong background in Quality Assurance will enhance Frontier’s reputation as a leading CRO in China.  In addition to his years of experience, Joe has earned the distinction of being recognized as a Registered Quality Assurance Professional by the Society of Quality Assurance (2007 through 2013), among other professional affiliations.

“Joe’s experience in Quality Assurance will increase Frontier’s emphasis on exceptional, quality data, and his unwavering commitment to quality will afford him great insight in continuously improving the company’s high quality standards,” said Chief Operating Officer of Frontier, Li Tian, PhD.

Mr. Stashick earned his BS in Biochemistry from the University of Maryland in College Park, Maryland.

About Frontier BioSciences, Inc.  Frontier BioSciences, Inc. is headquartered in the US with laboratory facilities in Chengdu and Kunming China.  Frontier provides a full spectrum of drug discovery and development resources to biotechnology and pharmaceutical industries in the scientific disciplines of GLP-compliant toxicology, developmental and reproductive toxicology, pharmacology, genetic toxicology, pathology, analytical chemistry and international regulatory guidance

With his current position, Dr. Walker will further expand upon and broaden Frontier’s extensive experience and knowledge of U.S. CRO standards and practices, especially in the areas of primate toxicology, infusion techniques in multiple species, surgical support, and animal model development, and contribute to the modernization of China’s rapidly-emerging market for drug safety and development.

“Mark’s toxicology and lab animal medicine experience, along with his U.S. CRO background and his enthusiasm for business challenges and team-based success, will serve him well at Frontier here in Chengdu,” said Dr. Dong Xie, CEO of Frontier. “His experience in business development, professional advancement, and customer management will be a valuable asset as well.”

Dr. Walker earned his degrees in Doctor of Veterinary Medicine and B.S. in Veterinary Science from Texas A&M University in College Station, Texas. He completed a postdoctoral residency in Comparative Pathobiology and Primate Medicine/Surgery from Bowman Grey School of Medicine prior to joining Hazleton Laboratories in Vienna, Virginia, in 1990.

About Frontier BioSciences, Inc.

Frontier BioSciences, Inc., with headquarters in Maryland, U.S.A., and toxicology facilities in Chengdu and Kunming, China, provides a full spectrum of drug discovery and development resources to biotechnology and pharmaceutical industries in the scientific disciplines of GLP-compliant toxicology, developmental and reproductive toxicology, pharmacology, genetic toxicology, pathology, analytical chemistry and international regulatory guidance.

For more information, contact:

Beth Wong
VP, Marketing and Business Development
Frontier BioSciences, Inc.
20251 Century Blvd, Suite 325
Germantown, MD 20874
301-515-5560